XML 47 R18.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Share-Based Compensation | 9 Months Ended
--- | ---
Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
Share-Based Compensation | Share-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, RSUs and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, an increase of the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan. During the three and nine months ended December 31, 2018, pre-tax share-based compensation costs charged against income were $1.9 million and $6.2 million, respectively, and the related income tax benefit recognized was $0.3 million and $1.1 million, respectively. During the three and nine months ended December 31, 2017, pre-tax share-based compensation costs charged against income were $2.2 million and $6.9 million, respectively, and the related income tax recognized was an expense of $0.1 million and a benefit of $1.4 million, respectively. At December 31, 2018, there were $7.6 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted average period of 1.0 year. The total fair value of options and RSUs vested during the nine months ended December 31, 2018 and 2017 was $12.0 million and $6.8 million, respectively. For the nine months ended December 31, 2018 and 2017, we received cash from the exercise of stock options of $2.9 million and $1.5 million, respectively. For the nine months ended December 31, 2018 and 2017, we realized $1.3 million and $1.1 million, respectively, in tax benefits from the tax deductions resulting from RSU issuances and stock option exercises. At December 31, 2018, there were 1.8 million shares available for issuance under the Plan. On May 7, 2018, the Compensation and Talent Management Committee of our Board of Directors granted 103,406 performance stock units, 100,399 RSUs and stock options to acquire 294,484 shares of our common stock to certain executive officers and employees under the Plan. The stock options were granted at an exercise price of $29.46 per share, which was equal to the closing price for our common stock on the date of the grant. Each of the independent members of the Board of Directors received a grant under the Plan of 3,779 RSUs on July 31, 2018. Restricted Stock Units RSUs granted to employees under the Plan generally vest in three years, primarily upon the attainment of certain time vesting thresholds, and, in the case of performance share units, may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The RSUs provide for accelerated vesting if there is a change of control, as defined in the Plan. The RSUs granted to employees generally vest either ratably over three years or in their entirety on the three-year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the RSUs, unless otherwise accelerated by the Compensation and Talent Management Committee or, in the case of RSUs granted in May 2017 and 2018, subject to pro-rata vesting in the event of death, disability or retirement. The RSUs granted to directors vest immediately upon grant, and will be settled by delivery to the director of one share of our common stock for each vested RSU promptly following the earliest of the (i) director's death, (ii) director's disability or (iii) six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the Plan is presented below:
RSUs |  | Shares (in thousands) |  | Weighted Average Grant-Date Fair Value
Nine Months Ended December 31, 2017 |  |  |  |
Vested and nonvested at March 31, 2017 |  | 350.1 |  |  | $ | 39.29 |
Granted |  | 105.8 |  |  | 55.61 |
Vested and issued |  | (53.3 | ) |  | 34.30 |
Forfeited |  | (8.8 | ) |  | 48.49 |
Vested and nonvested at December 31, 2017 |  | 393.8 |  |  | 44.14 |
Vested at December 31, 2017 |  | 90.5 |  |  | 29.88 |
Nine Months Ended December 31, 2018 |  |  |  |
Vested and nonvested at March 31, 2018 |  | 393.5 |  |  | $ | 44.13 |
Granted |  | 226.4 |  |  | 30.09 |
Vested and issued |  | (175.8 | ) |  | 43.05 |
Forfeited |  | (31.1 | ) |  | 48.32 |
Vested and nonvested at December 31, 2018 |  | 413.0 |  |  | 36.58 |
Vested at December 31, 2018 |  | 113.2 |  |  | 31.05 |
Options The Plan provides that the exercise price of options granted shall be no less than the fair market value of our common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Except in the case of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the nonvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan. The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options. The weighted average grant-date fair values of the options granted during the nine months ended December 31, 2018 and 2017 were $10.22 and $21.20, respectively.
|  | Nine Months Ended December 31,
|  | 2018 |  | 2017
Expected volatility |  | 29.6 | % |  | 35.2 | %
Expected dividends |  | $ | — |  |  | $ | — |
Expected term in years |  | 6.0 |  |  | 6.0 |
Risk-free rate |  | 2.9 | % |  | 2.2 | %
A summary of option activity under the Plan is as follows:
Options |  | Shares (in thousands) |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (years) |  | Aggregate Intrinsic Value (in thousands)
Nine Months Ended December 31, 2017 |  |  |  |  |  |  |  |
Outstanding at March 31, 2017 |  | 772.3 |  |  | $ | 37.70 |  |  |  |  |
Granted |  | 182.8 |  |  | 56.11 |  |  |  |  |
Exercised |  | (51.0 | ) |  | 28.76 |  |  |  |  |
Forfeited or expired |  | (22.1 | ) |  | 48.15 |  |  |  |  |
Outstanding at December 31, 2017 |  | 882.0 |  |  | 41.77 |  |  | 7.2 |  | $ | 7,019 |
Exercisable at December 31, 2017 |  | 502.9 |  |  | 32.50 |  |  | 6.1 |  | $ | 6,884 |
Nine Months Ended December 31, 2018 |  |  |  |  |  |  |  |  |  |  |
Outstanding at March 31, 2018 |  | 873.2 |  |  | $ | 41.79 |  |  |  |  |
Granted |  | 294.5 |  |  | 29.46 |  |  |  |  |
Exercised |  | (97.7 | ) |  | 30.02 |  |  |  |  |
Forfeited or expired |  | (125.4 | ) |  | 47.16 |  |  |  |  |
Outstanding at December 31, 2018 |  | 944.6 |  |  | 38.45 |  |  | 7.2 |  | $ | 2,477 |
Exercisable at December 31, 2018 |  | 499.4 |  |  | 37.87 |  |  | 5.8 |  | $ | 2,076 |
The aggregate intrinsic value of options exercised during the nine months ended December 31, 2018 was $0.8 million.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration